As Ultragenyx Pharmaceutical In (RARE) Market Value Rose, Guggenheim Capital Decreased Its Stake; Shareholder Penn Davis Mcfarland Raised Celgene (CELG) Holding

May 18, 2018 - By Dolores Ford

Celgene Corporation (NASDAQ:CELG) Logo

Guggenheim Capital Llc decreased its stake in Ultragenyx Pharmaceutical In (RARE) by 17.24% based on its latest 2017Q4 regulatory filing with the SEC. Guggenheim Capital Llc sold 11,892 shares as the company’s stock rose 2.87% while stock markets declined. The institutional investor held 57,102 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $2.65 million, down from 68,994 at the end of the previous reported quarter. Guggenheim Capital Llc who had been investing in Ultragenyx Pharmaceutical In for a number of months, seems to be less bullish one the $3.19 billion market cap company. The stock increased 0.38% or $0.24 during the last trading session, reaching $64.18. About 509,715 shares traded or 7.18% up from the average. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 29.39% since May 18, 2017 and is downtrending. It has underperformed by 40.94% the S&P500.

Penn Davis Mcfarland Inc increased its stake in Celgene Corporation (CELG) by 149.89% based on its latest 2017Q4 regulatory filing with the SEC. Penn Davis Mcfarland Inc bought 101,686 shares as the company’s stock declined 19.30% with the market. The institutional investor held 169,526 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $17.69M, up from 67,840 at the end of the previous reported quarter. Penn Davis Mcfarland Inc who had been investing in Celgene Corporation for a number of months, seems to be bullish on the $58.09 billion market cap company. The stock decreased 1.70% or $1.38 during the last trading session, reaching $79.98. About 8.53M shares traded or 20.50% up from the average. Celgene Corporation (NASDAQ:CELG) has declined 31.28% since May 18, 2017 and is downtrending. It has underperformed by 42.83% the S&P500.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 1 Sell and 14 Hold. Therefore 57% are positive. Celgene Corporation had 146 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald downgraded the stock to “Neutral” rating in Friday, October 27 report. The company was maintained on Tuesday, April 19 by Credit Suisse. The rating was maintained by Morgan Stanley with “Underweight” on Monday, October 23. As per Thursday, July 27, the company rating was maintained by Cantor Fitzgerald. As per Thursday, June 1, the company rating was maintained by Mizuho. As per Friday, October 20, the company rating was maintained by Barclays Capital. The firm has “Buy” rating by SunTrust given on Friday, December 22. The rating was maintained by Cowen & Co on Tuesday, September 12 with “Buy”. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, January 23 report. On Friday, October 27 the stock rating was maintained by Barclays Capital with “Equal-Weight”.

Since February 8, 2018, it had 1 buy, and 3 sales for $3.58 million activity. Alles Mark J also bought $299,594 worth of Celgene Corporation (NASDAQ:CELG) on Thursday, February 8. LOUGHLIN JAMES J also sold $851,093 worth of Celgene Corporation (NASDAQ:CELG) on Monday, March 12. 18,500 shares were sold by KAPLAN GILLA, worth $1.77M on Thursday, February 15.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Celgene And Otezla Are Cracking” on May 14, 2018, also Seekingalpha.com with their article: “Celgene Earnings Preview” published on April 30, 2018, Seekingalpha.com published: “Generic Revlimid Could Sink Celgene” on May 16, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Bizjournals.com and their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Celgene’s (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)” with publication date: May 16, 2018.

Investors sentiment decreased to 0.83 in Q4 2017. Its down 0.34, from 1.17 in 2017Q3. It dropped, as 156 investors sold CELG shares while 478 reduced holdings. 118 funds opened positions while 411 raised stakes. 561.38 million shares or 7.06% less from 603.99 million shares in 2017Q3 were reported. Argent Tru reported 0.57% in Celgene Corporation (NASDAQ:CELG). Wetherby Asset has invested 0.2% in Celgene Corporation (NASDAQ:CELG). Moreover, Da Davidson And Company has 0.11% invested in Celgene Corporation (NASDAQ:CELG) for 50,393 shares. Sumitomo Mitsui Tru Hldg has invested 0.31% in Celgene Corporation (NASDAQ:CELG). Boston Advsrs Ltd invested 0.53% of its portfolio in Celgene Corporation (NASDAQ:CELG). Sky Inv Grp Inc Ltd Llc has invested 0.22% in Celgene Corporation (NASDAQ:CELG). Spinnaker owns 16,446 shares for 0.2% of their portfolio. Taylor Asset Mngmt Inc owns 162,200 shares. Edinburgh Partners Ltd holds 8.7% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 315,906 shares. Kelly Lawrence W & Assoc Ca has invested 2.6% in Celgene Corporation (NASDAQ:CELG). Jp Marvel Inv Limited Liability Company reported 62,390 shares or 1.98% of all its holdings. Stifel Fincl invested in 0.42% or 1.26M shares. Oppenheimer Asset Management holds 0.41% or 106,435 shares in its portfolio. Prudential Financial reported 2.24M shares stake. 31 were accumulated by Delta Asset Mgmt Ltd Tn.

More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 11, 2018, also Nasdaq.com with their article: “Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita …” published on May 17, 2018, Seekingalpha.com published: “Ultragenyx Pharmaceuticals: Many Upcoming Catalysts” on May 09, 2018. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Streetinsider.com and their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018 as well as Nasdaq.com‘s news article titled: “Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the US for the Treatment of X …” with publication date: April 30, 2018.

Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on July, 26. They expect $-2.10 earnings per share, down 22.09% or $0.38 from last year’s $-1.72 per share. After $0.62 actual earnings per share reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -438.71% negative EPS growth.

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.06, from 1.19 in 2017Q3. It is positive, as 14 investors sold RARE shares while 42 reduced holdings. 19 funds opened positions while 51 raised stakes. 42.32 million shares or 6.46% more from 39.75 million shares in 2017Q3 were reported. Cap Research Glob reported 0.07% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Brown Advisory Incorporated holds 0.05% or 353,302 shares in its portfolio. Profund Limited Liability Co reported 15,764 shares. Us Natl Bank De has invested 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Global X Mgmt Com Ltd Liability Corp has 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 500 shares. The New York-based Tower Research Capital Limited Liability Com (Trc) has invested 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). American Century reported 35,723 shares or 0% of all its holdings. Edge Wealth Management Limited Liability Corp owns 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 300 shares. Cap World accumulated 510,000 shares. Barclays Public Lc owns 8,983 shares or 0% of their US portfolio. Citadel Advisors Llc owns 294,360 shares. Great West Life Assurance Can holds 0% or 6,219 shares in its portfolio. Qs Invsts Lc reported 907 shares or 0% of all its holdings. Jane Street Grp Limited Company holds 0% or 8,821 shares in its portfolio. Schwab Charles Investment Mngmt Incorporated has invested 0.01% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: